Vivek Subbiah: Wow! What an amazing event on “Shaping the future of personalised healthcare for cancer patients”
Vivek Subbiah, posted the following on LinkedIn:
“Wow! What an amazing event on ‘Shaping the future of personalised healthcare for cancer patients’ by a global multi-disciplinary panel of experts
Had a terrific time Chairing this spectacular event prime time at the ESMO – European Society for Medical Oncology 2023 Roche Industry Satellite Symposium
It was a spectacular evening of forward-thinking presentations & discussions with key leaders about recent advancements in precision oncology & evolving healthcare systems for bringing personalised medicine to cancer patients Dr Vivek Muthu, Benedikt Westphalen, World CUP Awareness & Linda Mileshkin, David Thomas & many more amazing colleagues
Precision Medicine for the win.”
Source: Vivek Subbiah/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023